Project ID: D2007-12U.S. Patent #8,211,858; Canada, European patents pendingU.S. Patent #7,592,422; Canada, France, Germany, Netherlands, UK patents pendingNovelty: Modified plasminogen activator inhibitor type I (PAI- 1) with significantly increased in vivo half-life and decreased activity to uroki.....
[更多]
Researchers at Oklahoma State havedeveloped a method that can induce 90% differentiation of iPSCs or MSCs intoAECs (type II) under stimulation of proper growth factors and growing on anappropriate matrix. These cells expressed type II cell markers surfactantprotein C and ABCA3, secrete lung surfacta.....
[更多]
• Fast and cost-effective fabrication process • Light-weight, strong, low-thermal-expansion optical components • General applicability to optics with different structures and material compositions
[更多]
A novel immunotherapeutic approach against drug-resistant pathogens, such as Neisseria gonorrhoeae, comprising administration to a subject a fusion protein linking Factor H to IgG Fc.
[更多]
The technology is a fiber-format picosecond light source for coherent anti-Stokes Raman scattering microscopy.
[更多]
| |< <- | [3112] [3113] [3114] [3115] [3116] [3117] [3118] [3119] [3120] [3121] [3122] | -> >| |
